Cardiogenics Holding (CGNH) 0.1150 $CGNH
CORRECTING AND REPLACING -- CardioGenics Announces $1.3 Million Private Placement to European Investors
GlobeNewswire - Thu Jun 12, 4:00PM CDT
Please replace the release with the following corrected version due to an incorrect date in the last paragraph of the release, which should read "... late July 2014" instead of "... late July 2013."
CardioGenics Announces $1.3 Million Private Placement to European Investors
GlobeNewswire - Thu Jun 12, 9:04AM CDT
CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the QL Care(TM) analyzer, an ultra-sensitive immunoassay point-of-care analyzer, and other products targeting the In-Vitro Diagnostics testing market, today announced it has sold $1.3 million of its common stock in a private placement to European institutional and other investors. Closing of the transaction is subject to listing of the shares on the NewConnect Market of the Warsaw Stock Exchange. WDM acted as offering agent and leading financial advisor on the transaction.
Small-Cap Specialists Issues New Research Report With Stocks on Watch
Marketwire - Mon Aug 26, 7:01AM CDT
Tucows, Inc. (NYSE MKT: TCX) is a global Internet services company. OpenSRS manages over fourteen million domain names and millions of value-added services through a reseller network of over 13,000 web hosts and ISPs. The company has reported its thirteenth consecutive quarter of revenue growth. Read about TCX's financial results and see a full report on company developments at the following link: http://bit.ly/REPORT-TCX
CardioGenics Announces Commencement of Beta-Site Testing
GlobeNewswire - Wed Aug 21, 8:00AM CDT
Beta-Site Testing of the Company's QL Care(TM) Analyzer and Troponin-I Test Begins in Two Hospitals
CardioGenics Announces Schedule for Beta-Site Testing
GlobeNewswire - Wed Jul 10, 8:00AM CDT
CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay Point-Of-Care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that beta-site testing of its QL Care(TM) Analyzer and Troponin-I test is scheduled to commence at hospitals affiliated with Wayne State University during the month of July 2013. The Company expects this testing program to be completed within 8-12 weeks.
CardioGenics Announces Internal Review Board Approval for Beta-Site Testing
PR Newswire - Wed Jun 05, 8:05AM CDT
CardioGenics Holdings Inc. (OTCBB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay Point-Of-Care Analyzer, and other products targeting the In-Vitro-Diagnostics testing market, announced today that it has received approval of its clinical testing protocol from the Institutional Review Board of Wayne State University ("IRB"
, which approval now enables the Company to commence beta-site testing of its QL Care(TM) Analyzer and first cardiovascular test, Troponin-I.
CORRECTING AND REPLACING -- CardioGenics Announces $1.3 Million Private Placement to European Investors
GlobeNewswire - Thu Jun 12, 4:00PM CDT
Please replace the release with the following corrected version due to an incorrect date in the last paragraph of the release, which should read "... late July 2014" instead of "... late July 2013."
CardioGenics Announces $1.3 Million Private Placement to European Investors
GlobeNewswire - Thu Jun 12, 9:04AM CDT
CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the QL Care(TM) analyzer, an ultra-sensitive immunoassay point-of-care analyzer, and other products targeting the In-Vitro Diagnostics testing market, today announced it has sold $1.3 million of its common stock in a private placement to European institutional and other investors. Closing of the transaction is subject to listing of the shares on the NewConnect Market of the Warsaw Stock Exchange. WDM acted as offering agent and leading financial advisor on the transaction.
Small-Cap Specialists Issues New Research Report With Stocks on Watch
Marketwire - Mon Aug 26, 7:01AM CDT
Tucows, Inc. (NYSE MKT: TCX) is a global Internet services company. OpenSRS manages over fourteen million domain names and millions of value-added services through a reseller network of over 13,000 web hosts and ISPs. The company has reported its thirteenth consecutive quarter of revenue growth. Read about TCX's financial results and see a full report on company developments at the following link: http://bit.ly/REPORT-TCX
CardioGenics Announces Commencement of Beta-Site Testing
GlobeNewswire - Wed Aug 21, 8:00AM CDT
Beta-Site Testing of the Company's QL Care(TM) Analyzer and Troponin-I Test Begins in Two Hospitals
CardioGenics Announces Schedule for Beta-Site Testing
GlobeNewswire - Wed Jul 10, 8:00AM CDT
CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay Point-Of-Care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that beta-site testing of its QL Care(TM) Analyzer and Troponin-I test is scheduled to commence at hospitals affiliated with Wayne State University during the month of July 2013. The Company expects this testing program to be completed within 8-12 weeks.
CardioGenics Announces Internal Review Board Approval for Beta-Site Testing
PR Newswire - Wed Jun 05, 8:05AM CDT
CardioGenics Holdings Inc. (OTCBB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay Point-Of-Care Analyzer, and other products targeting the In-Vitro-Diagnostics testing market, announced today that it has received approval of its clinical testing protocol from the Institutional Review Board of Wayne State University ("IRB"
, which approval now enables the Company to commence beta-site testing of its QL Care(TM) Analyzer and first cardiovascular test, Troponin-I. 
